ReviewACS omega2026
Advanced Propolis Delivery: Strategies for Improved Bioavailability and Therapeutic Efficacy.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Redox-Regulating Propolis- and Honey-Containing Hydrogels in Osteoarthritis.Antioxidants (Basel, Switzerland) · 2026Review
- Biocompatible Cyclodextrin-Cannabinoid Agar-Xanthan Gum Hydrogels for Controlled Delivery and Antimicrobial Soft-Tissue Biomedical Applications.ACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Propolis, a natural resinous product of honeybees, exhibits a wide range of biological activities, including antimicrobial, anti-inflammatory, antioxidant, and antifungal effects. However, its clinical application is limited by poor water solubility, high viscosity, and low bioavailability. To address these challenges, advanced drug delivery systems (DDS) such as nanoparticles, liposomes, hydrogels, niosomes, and self-microemulsifying systems have been developed to enhance the stability, solubility, and targeted delivery of propolis and its bioactive compounds. Lipid-based carriers and nanostructured systems have demonstrated improved mucosal penetration, cellular uptake, and controlled release profiles, leading to enhanced therapeutic efficacy against pathogens, cancer cells, and inflammatory conditions. Propolis-based formulations have shown promising applications in wound healing, oral delivery, dermatology, metabolic disorders, and hair growth. Additionally, propolis has emerged as a functional carrier matrix in DDS, contributing both structural and therapeutic benefits. Computational modeling and novel formulation strategies further support the optimization of propolis-based systems. Despite these advancements, challenges remain regarding formulation stability, safety, and clinical validation, including concerns related to allergic reactions. Future perspectives highlight the importance of integrating propolis into sustainable, multifunctional DDS and adopting holistic, personalized treatment approaches supported by artificial intelligence. Overall, propolis represents a versatile and promising component in the development of next-generation drug-delivery platforms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.